An Overview of Similarities and Differences in Metabolic Actions and Effects of Central Nervous System Between Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Sodium Glucose Co-Transporter-2 Inhibitors (SGLT-2is)

Song Wen, Thiquynhnga Nguyen, Min Gong, Xinlu Yuan, Chaoxun Wang, Jianlan Jin, Ligang Zhou, Song Wen, Thiquynhnga Nguyen, Min Gong, Xinlu Yuan, Chaoxun Wang, Jianlan Jin, Ligang Zhou

Abstract

GLP-1 receptor agonists (GLP-1RAs) and SGLT-2 inhibitors (SGLT-2is) are novel antidiabetic medications associated with considerable cardiovascular benefits therapying treatment of diabetic patients. GLP-1 exhibits atherosclerosis resistance, whereas SGLT-2i acts to ameliorate the neuroendocrine state in the patients with chronic heart failure. Despite their distinct modes of action, both factors share pathways by regulating the central nervous system (CNS). While numerous preclinical and clinical studies have demonstrated that GLP-1 can access various nuclei associated with energy homeostasis and hedonic eating in the CNS via blood-brain barrier (BBB), research on the activity of SGLT-2is remains limited. In our previous studies, we demonstrated that both GLP-1 receptor agonists (GLP-1RAs) liraglutide and exenatide, as well as an SGLT-2i, dapagliflozin, could activate various nuclei and pathways in the CNS of Sprague Dawley (SD) rats and C57BL/6 mice, respectively. Moreover, our results revealed similarities and differences in neural pathways, which possibly regulated different metabolic effects of GLP-1RA and SGLT-2i via sympathetic and parasympathetic systems in the CNS, such as feeding, blood glucose regulation and cardiovascular activities (arterial blood pressure and heart rate control). In the present article, we extensively discuss recent preclinical studies on the effects of GLP-1RAs and SGLT-2is on the CNS actions, with the aim of providing a theoretical explanation on their mechanism of action in improvement of the macro-cardiovascular risk and reducing incidence of diabetic complications. Overall, these findings are expected to guide future drug design approaches.

Keywords: autonomic nervous system; brain nuclei; cardiovascular diseases; diabetes; diabetic complications; obesity.

Conflict of interest statement

The authors report no conflicts of interest in this work.

© 2021 Wen et al.

Figures

Figure 1
Figure 1
An overview and comparison of major effects of GLP-1RAs and SGLT-2is. The figure summarizes major clinical effects of both antidiabetic drugs on the energy homeostasis and complication management, with regards to macrovascular, microvascular, peripheral nervous system, adipose tissue homeostasis, and insulin secretion and glycemic control. *GLP-1RAs significantly reduce diabetic foot ulcer- related amputations. #SGLT2is significantly increase total cholesterol, LDL-C, non-HDL-C, and HDL-C and decrease triglyceride.
Figure 2
Figure 2
A mechanistic comparison of central and peripheral pathways related to the treatment outcomes by GLP-1RAs and SGLT-2is. As showing in the left side of the figure, GLP-1RAs influences energy setpoint of the hypothalamus, and may limit food intake, decrease body weight, promote insulin secretion and energy expenditure by increasing adipose tissue browning. They can also increase PNS activity, and exert effects of anti-atherosclerosis, which could benefit cardiovascular system. As the right side of the figure showing, SGLT-2is influence glucose absorption and inhibit energy expenditure. They also promote renal tubule-glomerular feedback, decrease the blood volume, and reduce the renal stress, which interacts with SNS and RAAS. Besides, SGLT-2is may activate specific sensing neurons and certain neural pathways in the CNS, thereby suppressing the SNS, regulating cardiovascular activity.

References

    1. Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet. 2017;389(10085):2239–2251. doi:10.1016/S0140-6736(17)30058-2
    1. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773–795. doi:10.2337/db09-9028
    1. Ahlqvist E, Storm P, Käräjämäki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018;6(5):361–369. doi:10.1016/S2213-8587(18)30051-2
    1. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–2471. doi:10.1056/NEJMoa072761
    1. Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA. SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME Study. Diabetes Care. 2016;39(5):717–725. doi:10.2337/dc16-0041
    1. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322. doi:10.1056/NEJMoa1603827
    1. American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl1):S111–s124. doi:10.2337/dc21-S009
    1. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci U S A. 1992;89(18):8641–8645. doi:10.1073/pnas.89.18.8641
    1. Thorens B, Porret A, Bühler L, Deng SP, Morel P, Widmann C. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes. 1993;42(11):1678–1682. doi:10.2337/diab.42.11.1678
    1. Nishizawa M, Nakabayashi H, Uehara K, Nakagawa A, Uchida K, Koya D. Intraportal GLP-1 stimulates insulin secretion predominantly through the hepatoportal-pancreatic vagal reflex pathways. Am J Physiol Endocrinol Metab. 2013;305(3):E376–387. doi:10.1152/ajpendo.00565.2012
    1. Gautier JF, Choukem SP, Girard J. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes Metab. 2008;34(Suppl 2):S65–72. doi:10.1016/S1262-3636(08)73397-4
    1. Göke R, Fehmann HC, Linn T, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem. 1993;268(26):19650–19655. doi:10.1016/S0021-9258(19)36565-2
    1. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409–1439. doi:10.1152/physrev.00034.2006
    1. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131–2157. doi:10.1053/j.gastro.2007.03.054
    1. Aulinger BA, Vahl TP, Prigeon RL, D’Alessio DA, Elder DA. The incretin effect in obese adolescents with and without type 2 diabetes: impaired or intact? Am J Physiol Endocrinol Metab. 2016;310(9):E774–781. doi:10.1152/ajpendo.00496.2015
    1. Holst JJ, Vilsbøll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol. 2009;297(1–2):127–136. doi:10.1016/j.mce.2008.08.012
    1. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91(2):733–794.
    1. Koekkoek LL, Mul JD, la Fleur SE. Glucose-sensing in the reward system. Front Neurosci. 2017;11:716. doi:10.3389/fnins.2017.00716
    1. Yu AS, Hirayama BA, Timbol G, et al. Functional expression of SGLTs in rat brain. Am J Physiol Cell Physiol. 2010;299(6):C1277–1284. doi:10.1152/ajpcell.00296.2010
    1. Yu AS, Hirayama BA, Timbol G, et al. Regional distribution of SGLT activity in rat brain in vivo. Am J Physiol Cell Physiol. 2013;304(3):C240–C247. doi:10.1152/ajpcell.00317.2012
    1. Gonzàlez JA, Reimann F, Burdakov D. Dissociation between sensing and metabolism of glucose in sugar sensing neurones. J Physiol. 2009;587(1):41–48. doi:10.1113/jphysiol.2008.163410
    1. O’Malley D, Reimann F, Simpson AK, Gribble FM. Sodium-coupled glucose cotransporters contribute to hypothalamic glucose sensing. Diabetes. 2006;55(12):3381–3386. doi:10.2337/db06-0531
    1. Scafoglio C, Hirayama BA, Kepe V, et al. Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci U S A. 2015;112(30):E4111–4119. doi:10.1073/pnas.1511698112
    1. Elliott RH, Matthews VB, Rudnicka C, Schlaich MP. Is it time to think about the sodium glucose co-transporter 2 sympathetically? Nephrology (Carlton). 2016;21(4):286–294. doi:10.1111/nep.12620
    1. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854–865. doi:10.1016/S0140-6736(98)07037-8
    1. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–2559.
    1. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589. doi:10.1056/NEJMoa0806470
    1. Lugner M, Sattar N, Miftaraj M, et al. Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study. Cardiovasc Diabetol. 2021;20(1):67. doi:10.1186/s12933-021-01258-x
    1. Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;372:m4573. doi:10.1136/bmj.m4573
    1. Andrikou E, Tsioufis C, Andrikou I, Leontsinis I, Tousoulis D, Papanas N. GLP-1 receptor agonists and cardiovascular outcome trials: an update. Hellenic J Cardiol. 2019;60(6):347–351.
    1. Boyle JG, Livingstone R, Petrie JR. Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review. Clin Sci (Lond). 2018;132(15):1699–1709. doi:10.1042/CS20171299
    1. Kario K, Okada K, Kato M, et al. 24-hour blood pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the Randomized, Placebo-Controlled SACRA Study. Circulation. 2018;139(18):2089–2097. doi:10.1161/CIRCULATIONAHA.118.037076
    1. Pereira MJ, Eriksson JW. Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs. 2019;79(3):219–230. doi:10.1007/s40265-019-1057-0
    1. Sánchez-García A, Simental-Mendía M, Millán-Alanís JM, Simental-Mendía LE. Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: a systematic review and meta-analysis of 48 randomized controlled trials. Pharmacol Res. 2020;160:105068. doi:10.1016/j.phrs.2020.105068
    1. Ninčević V, Omanović Kolarić T, Roguljić H, Kizivat T, Smolić M, Bilić Ćurčić I. Renal benefits of SGLT 2 inhibitors and GLP-1 receptor agonists: evidence supporting a paradigm shift in the medical management of type 2 diabetes. Int J Mol Sci. 2019;20(23):5831. doi:10.3390/ijms20235831
    1. Ali AM, Mari A, Martinez R, et al. Improved beta cell glucose sensitivity plays predominant role in the decrease in HbA1c with Cana and Lira in T2DM. J Clin Endocrinol Metab. 2020;105(10):3226–3233. doi:10.1210/clinem/dgaa494
    1. Mehta K, Behl T, Kumar A, Uddin MS, Zengin G, Arora S. Deciphering the neuroprotective role of glucagon-like Peptide-1 agonists in diabetic neuropathy: current perspective and future directions. Curr Protein Pept Sci. 2021;22(1):4–18. doi:10.2174/1389203721999201208195901
    1. Dorsey-Treviño EG, González-González JG, Alvarez-Villalobos N, et al. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis. J Endocrinol Invest. 2020;43(3):289–304. doi:10.1007/s40618-019-01103-9
    1. Chang HY, Singh S, Mansour O, Baksh S, Alexander GC. Association between sodium-glucose cotransporter 2 inhibitors and lower extremity amputation among patients with type 2 diabetes. JAMA Intern Med. 2018;178(9):1190–1198. doi:10.1001/jamainternmed.2018.3034
    1. Dhatariya K, Bain SC, Buse JB, et al. The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: results from the LEADER Trial. Diabetes Care. 2018;41(10):2229–2235. doi:10.2337/dc18-1094
    1. Avgerinos I, Karagiannis T, Malandris K, et al. Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2019;21(1):188–193. doi:10.1111/dom.13484
    1. Gaborit B, Julla JB, Besbes S, et al. Glucagon-like peptide 1 receptor agonists, diabetic retinopathy and angiogenesis: the angiosafe type 2 Diabetes Study. J Clin Endocrinol Metab. 2020;105(4):e1549–e1560. doi:10.1210/clinem/dgz069
    1. Patoulias D, Stavropoulos K, Imprialos K, et al. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: a systematic review and meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2019;158:107927. doi:10.1016/j.diabres.2019.107927
    1. Lajara R. Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes. Postgrad Med. 2019;131(8):555–565. doi:10.1080/00325481.2019.1670017
    1. Ikonomidis I, Pavlidis G, Thymis J, et al. Effects of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and their combination on endothelial glycocalyx, arterial function, and myocardial work index in patients with type 2 diabetes mellitus after 12-month treatment. J Am Heart Assoc. 2020;9(9):e015716. doi:10.1161/JAHA.119.015716
    1. Aroda VR. A review of GLP-1 receptor agonists: evolution and advancement, through the lens of randomised controlled trials. Diabetes Obes Metab. 2018;20(Suppl 1):22–33. doi:10.1111/dom.13162
    1. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–2257. doi:10.1056/NEJMoa1509225
    1. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. doi:10.1056/NEJMoa1504720
    1. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844. doi:10.1056/NEJMoa1607141
    1. Bain SC, Mosenzon O, Arechavaleta R, et al. Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: rationale, design and patient baseline characteristics for the PIONEER 6 trial. Diabetes Obes Metab. 2019;21(3):499–508. doi:10.1111/dom.13553
    1. Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228–1239. doi:10.1056/NEJMoa1612917
    1. Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519–1529.
    1. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–130.
    1. McKee A, Al-Khazaali A, Albert SG. Glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter inhibitors for treatment of T2DM. J Endocr Soc. 2020;4(5):bvaa037. doi:10.1210/jendso/bvaa037
    1. Sharma A, Verma S. Mechanisms by which glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors reduce cardiovascular risk in adults with type 2 diabetes mellitus. Can J Diabetes. 2020;44(1):93–102. doi:10.1016/j.jcjd.2019.09.003
    1. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657. doi:10.1056/NEJMoa1611925
    1. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357. doi:10.1056/NEJMoa1812389
    1. Hallow KM, Helmlinger G, Greasley PJ, McMurray JJV, Boulton DW. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab. 2018;20(3):479–487. doi:10.1111/dom.13126
    1. Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134(10):752–772. doi:10.1161/CIRCULATIONAHA.116.021887
    1. Takebayashi K, Inukai T. Effect of sodium glucose cotransporter 2 inhibitors with low SGLT2/SGLT1 selectivity on circulating glucagon-like peptide 1 levels in type 2 diabetes mellitus. J Clin Med Res. 2017;9(9):745–753. doi:10.14740/jocmr3112w
    1. INVOKANA® (canagliflozin) tablets, for oral use. Titusville, NJ, USA: Janssen Pharmaceuticals, Inc; 2013. Available from: . Accessed June 25, 2021.
    1. FARXIGA® (dapagliflozin) tablets, for oral use. Wilmington, DE, USA: AstraZeneca, Inc; 2014. Available from: .pdf. Accessed June 25, 2021.
    1. JARDIANCE® (empagliflozin) tablets, for oral use. Ridgefield, CT, USA: Boehringer Ingelheim Pharmaceuticals, Inc.; 2014. Available from: . Accessed June 25, 2021.
    1. Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab. 2016;18(8):783–794. doi:10.1111/dom.12670
    1. Cai X, Yang W, Gao X, et al. The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients: a meta-analysis. Obesity (Silver Spring). 2018;26(1):70–80. doi:10.1002/oby.22066
    1. Bolinder J, Ljunggren Ö, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014;16(2):159–169. doi:10.1111/dom.12189
    1. Bailey CJ, Morales Villegas EC, Woo V, Tang W, Ptaszynska A, List JF. Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial. Diabet Med. 2015;32(4):531–541. doi:10.1111/dme.12624
    1. Del Prato S, Nauck M, Durán-Garcia S, et al. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes Obes Metab. 2015;17(6):581–590. doi:10.1111/dom.12459
    1. Deol H, Lekkakou L, Viswanath AK, Pappachan JM. Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabesity: the real world experience. Endocrine. 2017;55(1):173–178. doi:10.1007/s12020-016-1125-0
    1. Saroka RM, Kane MP, Busch RS, Watsky J, Hamilton RA. SGLT-2 inhibitor therapy added to GLP-1 agonist therapy in the management of T2DM. Endocr Pract. 2015;21(12):1315–1322. doi:10.4158/EP15877.OR
    1. Gong M, Wen S, Nguyen T, Wang C, Jin J, Zhou L. Converging relationships of obesity and hyperuricemia with special reference to metabolic disorders and plausible therapeutic implications. Diabetes Metab Syndr Obes. 2020;13:943–962. doi:10.2147/DMSO.S232377
    1. Szablewski L. Glucose transporters in brain: in health and in Alzheimer’s disease. J Alzheimers Dis. 2017;55(4):1307–1320. doi:10.3233/JAD-160841
    1. Lim K, Jackson KL, Sata Y, Head GA. Factors responsible for obesity-related hypertension. Curr Hypertens Rep. 2017;19(7):53. doi:10.1007/s11906-017-0750-1
    1. Shirasaka T, Kunitake T, Takasaki M, Kannan H. Neuronal effects of orexins: relevant to sympathetic and cardiovascular functions. Regul Pept. 2002;104(1–3):91–95. doi:10.1016/S0167-0115(01)00352-4
    1. Dunbar JC, Hu Y, Lu H. Intracerebroventricular leptin increases lumbar and renal sympathetic nerve activity and blood pressure in normal rats. Diabetes. 1997;46(12):2040–2043. doi:10.2337/diab.46.12.2040
    1. Shek EW, Brands MW, Hall JE. Chronic leptin infusion increases arterial pressure. Hypertension. 1998;31(1 Pt 2):409–414. doi:10.1161/01.HYP.31.1.409
    1. Zhou L, Podolsky N, Sang Z, et al. The medial amygdalar nucleus: a novel glucose-sensing region that modulates the counterregulatory response to hypoglycemia. Diabetes. 2010;59(10):2646–2652. doi:10.2337/db09-0995
    1. Squillacioti C, Pelagalli A, Liguori G, Mirabella N. Urocortins in the mammalian endocrine system. Acta Vet Scand. 2019;61(1):46. doi:10.1186/s13028-019-0480-2
    1. Chatzaki E, Kefala N, Drosos I, Lalidou F, Baritaki S. Do urocortins have a role in treating cardiovascular disease? Drug Discov Today. 2019;24(1):279–284. doi:10.1016/j.drudis.2018.09.004
    1. Guivarc’h E, Buscato M, Guihot AL, et al. Predominant role of nuclear versus membrane estrogen receptor α in arterial protection: implications for estrogen receptor α modulation in cardiovascular prevention/safety. J Am Heart Assoc. 2018;7(13). doi:10.1161/JAHA.118.008950
    1. Gourdy P, Guillaume M, Fontaine C, et al. Estrogen receptor subcellular localization and cardiometabolism. Mol Metab. 2018;15:56–69. doi:10.1016/j.molmet.2018.05.009
    1. Ropero AB, Eghbali M, Minosyan TY, Tang G, Toro L, Stefani E. Heart estrogen receptor alpha: distinct membrane and nuclear distribution patterns and regulation by estrogen. J Mol Cell Cardiol. 2006;41(3):496–510. doi:10.1016/j.yjmcc.2006.05.022
    1. Wen S, Wang C, Gong M, Zhou L. An overview of energy and metabolic regulation. Sci China Life Sci. 2019;62(6):771–790. doi:10.1007/s11427-018-9371-4
    1. Waterson MJ, Horvath TL. Neuronal regulation of energy homeostasis: beyond the hypothalamus and feeding. Cell Metab. 2015;22(6):962–970. doi:10.1016/j.cmet.2015.09.026
    1. Berridge KC, Ho CY, Richard JM, DiFeliceantonio AG. The tempted brain eats: pleasure and desire circuits in obesity and eating disorders. Brain Res. 2010;1350:43–64.
    1. Kanoski SE, Hayes MR, Skibicka KP. GLP-1 and weight loss: unraveling the diverse neural circuitry. Am J Physiol Regul Integr Comp Physiol. 2016;310(10):R885–895. doi:10.1152/ajpregu.00520.2015
    1. Carlson SH, Wyss JM. Neurohormonal regulation of the sympathetic nervous system: new insights into central mechanisms of action. Curr Hypertens Rep. 2008;10(3):233–240. doi:10.1007/s11906-008-0044-8
    1. Benarroch EE. The central autonomic network: functional organization, dysfunction, and perspective. Mayo Clin Proc. 1993;68(10):988–1001. doi:10.1016/S0025-6196(12)62272-1
    1. Cechetto DF, Saper CB. Neurochemical organization of the hypothalamic projection to the spinal cord in the rat. J Comp Neurol. 1988;272(4):579–604. doi:10.1002/cne.902720410
    1. Yi SS, Kim HJ, Do SG, et al. Arginine vasopressin (AVP) expressional changes in the hypothalamic paraventricular and supraoptic nuclei of stroke-prone spontaneously hypertensive rats. Anat Cell Biol. 2012;45(2):114–120. doi:10.5115/acb.2012.45.2.114
    1. Kim YB, Kim YS, Kim WB, et al. GABAergic excitation of vasopressin neurons: possible mechanism underlying sodium-dependent hypertension. Circ Res. 2013;113(12):1296–1307. doi:10.1161/CIRCRESAHA.113.301814
    1. Choe KY, Han SY, Gaub P, et al. High salt intake increases blood pressure via BDNF-mediated downregulation of KCC2 and impaired baroreflex inhibition of vasopressin neurons. Neuron. 2015;85(3):549–560. doi:10.1016/j.neuron.2014.12.048
    1. Kawabe T, Kawabe K, Sapru HN. Cardiovascular responses to chemical stimulation of the hypothalamic arcuate nucleus in the rat: role of the hypothalamic paraventricular nucleus. PLoS One. 2012;7(9):e45180. doi:10.1371/journal.pone.0045180
    1. Kawabe T, Kawabe K, Sapru HN. Effect of barodenervation on cardiovascular responses elicited from the hypothalamic arcuate nucleus of the rat. PLoS One. 2012;7(12):e53111. doi:10.1371/journal.pone.0053111
    1. Kawabe T, Kawabe K, Sapru HN. Tonic γ-aminobutyric acid-ergic activity in the hypothalamic arcuate nucleus is attenuated in the spontaneously hypertensive rat. Hypertension. 2013;62(2):281–287. doi:10.1161/HYPERTENSIONAHA.113.01132
    1. Cardinale JP, Sriramula S, Mariappan N, Agarwal D, Francis J. Angiotensin II-induced hypertension is modulated by nuclear factor-κBin the paraventricular nucleus. Hypertension. 2012;59(1):113–121. doi:10.1161/HYPERTENSIONAHA.111.182154
    1. Sriramula S, Xia H, Xu P, Lazartigues E. Brain-targeted angiotensin-converting enzyme 2 overexpression attenuates neurogenic hypertension by inhibiting cyclooxygenase-mediated inflammation. Hypertension. 2015;65(3):577–586. doi:10.1161/HYPERTENSIONAHA.114.04691
    1. Yuan N, Zhang F, Zhang LL, et al. SOD1 gene transfer into paraventricular nucleus attenuates hypertension and sympathetic activity in spontaneously hypertensive rats. Pflugers Arch. 2013;465(2):261–270. doi:10.1007/s00424-012-1173-0
    1. Coleman CG, Wang G, Faraco G, et al. Membrane trafficking of NADPH oxidase p47(phox) in paraventricular hypothalamic neurons parallels local free radical production in angiotensin II slow-pressor hypertension. J Neurosci. 2013;33(10):4308–4316. doi:10.1523/JNEUROSCI.3061-12.2013
    1. Northcott CA, Billecke S, Craig T, et al. Nitric oxide synthase, ADMA, SDMA, and nitric oxide activity in the paraventricular nucleus throughout the etiology of renal wrap hypertension. Am J Physiol Heart Circ Physiol. 2012;302(11):H2276–2284. doi:10.1152/ajpheart.00562.2011
    1. Zhou YB, Sun HJ, Chen D, et al. Intermedin in paraventricular nucleus attenuates sympathetic activity and blood pressure via nitric oxide in hypertensive rats. Hypertension. 2014;63(2):330–337. doi:10.1161/HYPERTENSIONAHA.113.01681
    1. Huang BS, White RA, Leenen FH. Possible role of brain salt-inducible kinase 1 in responses to central sodium in Dahl rats. Am J Physiol Regul Integr Comp Physiol. 2012;303(2):R236–245. doi:10.1152/ajpregu.00381.2011
    1. Gabor A, Leenen FH. Central mineralocorticoid receptors and the role of angiotensin II and glutamate in the paraventricular nucleus of rats with angiotensin II-induced hypertension. Hypertension. 2013;61(5):1083–1090. doi:10.1161/HYPERTENSIONAHA.111.00797
    1. Harlan SM, Guo DF, Morgan DA, Fernandes-Santos C, Rahmouni K. Hypothalamic mTORC1 signaling controls sympathetic nerve activity and arterial pressure and mediates leptin effects. Cell Metab. 2013;17(4):599–606. doi:10.1016/j.cmet.2013.02.017
    1. Tanida M, Yamamoto N, Shibamoto T, Rahmouni K. Involvement of hypothalamic AMP-activated protein kinase in leptin-induced sympathetic nerve activation. PLoS One. 2013;8(2):e56660. doi:10.1371/journal.pone.0056660
    1. Carmichael CY, Wainford RD. Hypothalamic signaling mechanisms in hypertension. Curr Hypertens Rep. 2015;17(5):39. doi:10.1007/s11906-015-0550-4
    1. Reis DJ. The brain and hypertension: reflections on 35 years of inquiry into the neurobiology of the circulation. Circulation. 1984;70(5 Pt 2):Iii31–45.
    1. Morrison SF, Ernsberger P, Milner TA, Callaway J, Gong A, Reis DJ. A glutamate mechanism in the intermediolateral nucleus mediates sympathoexcitatory responses to stimulation of the rostral ventrolateral medulla. Prog Brain Res. 1989;81:159–169.
    1. Catelli JM, Giakas WJ, Sved AF. GABAergic mechanisms in nucleus tractus solitarius alter blood pressure and vasopressin release. Brain Res. 1987;403(2):279–289. doi:10.1016/0006-8993(87)90065-5
    1. Sawchenko PE, Swanson LW. Central noradrenergic pathways for the integration of hypothalamic neuroendocrine and autonomic responses. Science (New York, NY). 1981;214(4521):685–687. doi:10.1126/science.7292008
    1. Day TA. Control of neurosecretory vasopressin cells by noradrenergic projections of the caudal ventrolateral medulla. Prog Brain Res. 1989;81:303–317.
    1. Galosy RA, Clarke LK, Vasko MR, Crawford IL. Neurophysiology and neuropharmacology of cardiovascular regulation and stress. Neurosci Biobehav Rev. 1981;5(1):137–175.
    1. D’Alessio D. Is GLP-1 a hormone: whether and when? J Diabetes Investig. 2016;7 Suppl 1(Suppl1):50–55. doi:10.1111/jdi.12466
    1. Graham DL, Durai HH, Trammell TS, et al. A novel mouse model of glucagon-like peptide-1 receptor expression: a look at the brain. J Comp Neurol. 2020;528(14):2445–2470. doi:10.1002/cne.24905
    1. Merchenthaler I, Lane M, Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol. 1999;403(2):261–280. doi:10.1002/(SICI)1096-9861(19990111)403:2<261::AID-CNE8>;2-5
    1. Zheng H, Cai L, Rinaman L. Distribution of glucagon-like peptide 1-immunopositive neurons in human caudal medulla. Brain Struct Funct. 2015;220(2):1213–1219. doi:10.1007/s00429-014-0714-z
    1. Krieger JP, Arnold M, Pettersen KG, Lossel P, Langhans W, Lee SJ. Knockdown of GLP-1 receptors in vagal afferents affects normal food intake and glycemia. Diabetes. 2016;65(1):34–43. doi:10.2337/db15-0973
    1. Krieger JP, Langhans W, Lee SJ. Vagal mediation of GLP-1’s effects on food intake and glycemia. Physiol Behav. 2015;152(Pt B):372–380. doi:10.1016/j.physbeh.2015.06.001
    1. Diepenbroek C, Quinn D, Stephens R, et al. Validation and characterization of a novel method for selective vagal deafferentation of the gut. Am J Physiol Gastrointest Liver Physiol. 2017;313(4):G342–g352. doi:10.1152/ajpgi.00095.2017
    1. Vrang N, Larsen PJ. Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: role of peripherally secreted and centrally produced peptides. Prog Neurobiol. 2010;92(3):442–462. doi:10.1016/j.pneurobio.2010.07.003
    1. Katsurada K, Maejima Y, Nakata M, et al. Endogenous GLP-1 acts on paraventricular nucleus to suppress feeding: projection from nucleus tractus solitarius and activation of corticotropin-releasing hormone, nesfatin-1 and oxytocin neurons. Biochem Biophys Res Commun. 2014;451(2):276–281. doi:10.1016/j.bbrc.2014.07.116
    1. Alhadeff AL, Rupprecht LE, Hayes MR. GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology. 2012;153(2):647–658. doi:10.1210/en.2011-1443
    1. Renner E, Puskás N, Dobolyi A, Palkovits M. Glucagon-like peptide-1 of brainstem origin activates dorsomedial hypothalamic neurons in satiated rats. Peptides. 2012;35(1):14–22. doi:10.1016/j.peptides.2012.02.018
    1. Llewellyn-Smith IJ, Marina N, Manton RN, Reimann F, Gribble FM, Trapp S. Spinally projecting preproglucagon axons preferentially innervate sympathetic preganglionic neurons. Neuroscience. 2015;284:872–887. doi:10.1016/j.neuroscience.2014.10.043
    1. Zhang D, Lv G. Therapeutic potential of spinal GLP-1 receptor signaling. Peptides. 2018;101:89–94. doi:10.1016/j.peptides.2018.01.003
    1. Tudurí E, Nogueiras R. Insulinotropic actions of GLP-1: how much in the brain and how much in the periphery? Endocrinology. 2017;158(7):2071–2073. doi:10.1210/en.2017-00410
    1. Sisley S, Gutierrez-Aguilar R, Scott M, D’Alessio DA, Sandoval DA, Seeley RJ. Neuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect. J Clin Invest. 2014;124(6):2456–2463. doi:10.1172/JCI72434
    1. Umapathysivam MM, Lee MY, Jones KL, et al. Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia. Diabetes. 2014;63(2):785–790. doi:10.2337/db13-0893
    1. Brierley DI, Holt MK, Singh A, et al. Central and peripheral GLP-1 systems independently suppress eating. Nat Metab. 2021;3(2):258–273. doi:10.1038/s42255-021-00344-4
    1. Trapp S, Richards JE. The gut hormone glucagon-like peptide-1 produced in brain: is this physiologically relevant? Curr Opin Pharmacol. 2013;13(6):964–969. doi:10.1016/j.coph.2013.09.006
    1. Kanoski SE, Fortin SM, Arnold M, Grill HJ, Hayes MR. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology. 2011;152(8):3103–3112. doi:10.1210/en.2011-0174
    1. Jessen L, Smith EP, Ulrich-Lai Y, et al. Central nervous system GLP-1 receptors regulate islet hormone secretion and glucose homeostasis in male rats. Endocrinology. 2017;158(7):2124–2133. doi:10.1210/en.2016-1826
    1. Plamboeck A, Veedfald S, Deacon CF, et al. The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty. Am J Physiol Gastrointest Liver Physiol. 2013;304(12):G1117–1127. doi:10.1152/ajpgi.00035.2013
    1. Rüttimann EB, Arnold M, Hillebrand JJ, Geary N, Langhans W. Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology. 2009;150(3):1174–1181. doi:10.1210/en.2008-1221
    1. Fortin SM, Lipsky RK, Lhamo R, et al. GABA neurons in the nucleus tractus solitarius express GLP-1 receptors and mediate anorectic effects of liraglutide in rats. Sci Transl Med. 2020;12(533):eaay8071. doi:10.1126/scitranslmed.aay8071
    1. Adams JM, Pei H, Sandoval DA, Seeley RJ, Chang RB, Liberles SD. Olson DP: liraglutide modulates appetite and body weight through glucagon-like peptide 1 receptor-expressing glutamatergic neurons. Diabetes. 2018;67(8):1538–1548. doi:10.2337/db17-1385
    1. Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014;124(10):4473–4488. doi:10.1172/JCI75276
    1. Holt MK, Cook DR, Brierley DI, et al. PPG neurons in the nucleus of the solitary tract modulate heart rate but do not mediate GLP-1 receptor agonist-induced tachycardia in mice. Mol Metab. 2020;39:101024. doi:10.1016/j.molmet.2020.101024
    1. Gabery S, Salinas CG, Paulsen SJ, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5(6). doi:10.1172/jci.insight.133429
    1. Baraboi ED, St-Pierre DH, Shooner J, Timofeeva E, Richard D. Brain activation following peripheral administration of the GLP-1 receptor agonist exendin-4. Am J Physiol Regul Integr Comp Physiol. 2011;301(4):R1011–1024. doi:10.1152/ajpregu.00424.2010
    1. Wen S, Nguyen T, Xiao WZ, et al. Comparative study on anorexigenic effect of glucagon-like peptide-1 receptor agonists in rats. Sheng Li Xue Bao. 2019;71(4):514–526.
    1. Pérez-Tilve D, González-Matías L, Aulinger BA, et al. Exendin-4 increases blood glucose levels acutely in rats by activation of the sympathetic nervous system. Am J Physiol Endocrinol Metab. 2010;298(5):E1088–1096. doi:10.1152/ajpendo.00464.2009
    1. Barragán JM, Rodríguez RE, Eng J, Blázquez E. Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats. Regul Pept. 1996;67(1):63–68. doi:10.1016/S0167-0115(96)00113-9
    1. Kim M, Platt MJ, Shibasaki T, et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med. 2013;19(5):567–575. doi:10.1038/nm.3128
    1. Pyke C, Knudsen LB. The glucagon-like peptide-1 receptor--or not? Endocrinology. 2013;154(1):4–8. doi:10.1210/en.2012-2124
    1. Richards P, Parker HE, Adriaenssens AE, et al. Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model. Diabetes. 2014;63(4):1224–1233. doi:10.2337/db13-1440
    1. Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res. 2014;114(11):1788–1803. doi:10.1161/CIRCRESAHA.114.301958
    1. Yamamoto H, Lee CE, Marcus JN, et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest. 2002;110(1):43–52. doi:10.1172/JCI0215595
    1. Yamamoto H, Kishi T, Lee CE, et al. Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neurosci. 2003;23(7):2939–2946. doi:10.1523/JNEUROSCI.23-07-02939.2003
    1. Baggio LL, Ussher JR, McLean BA, et al. The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice. Mol Metab. 2017;6(11):1339–1349. doi:10.1016/j.molmet.2017.08.010
    1. Griffioen KJ, Wan R, Okun E, et al. GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons. Cardiovasc Res. 2011;89(1):72–78. doi:10.1093/cvr/cvq271
    1. Verma S, Bhatt DL, Bain SC, et al. Effect of liraglutide on cardiovascular events in patients with type 2 diabetes mellitus and polyvascular disease: results of the LEADER Trial. Circulation. 2018;137(20):2179–2183. doi:10.1161/CIRCULATIONAHA.118.033898
    1. Rizzo M, Nikolic D, Patti AM, et al. GLP-1 receptor agonists and reduction of cardiometabolic risk: potential underlying mechanisms. Biochim Biophys Acta Mol Basis Dis. 2018;1864(9 Pt B):2814–2821. doi:10.1016/j.bbadis.2018.05.012
    1. Basalay MV, Mastitskaya S, Mrochek A, et al. Glucagon-like peptide-1 (GLP-1) mediates cardioprotection by remote ischaemic conditioning. Cardiovasc Res. 2016;112(3):669–676. doi:10.1093/cvr/cvw216
    1. Chen J, Xu S, Wang L, et al. Exendin-4 inhibits atrial arrhythmogenesis in a model of myocardial infarction-induced heart failure via the GLP-1 receptor signaling pathway. Exp Ther Med. 2020;20(4):3669–3678. doi:10.3892/etm.2020.9089
    1. Verouhis D, Saleh N, Settergren M, Sörensson P, Gourine A, Pernow J. Remote ischemic conditioning protects against endothelial ischemia-reperfusion injury via a glucagon-like peptide-1 receptor-mediated mechanism in humans. Int J Cardiol. 2019;274:40–44. doi:10.1016/j.ijcard.2018.09.061
    1. He Z, Gao Y, Lieu L, et al. Direct and indirect effects of liraglutide on hypothalamic POMC and NPY/AgRP neurons - Implications for energy balance and glucose control. Mol Metab. 2019;28:120–134. doi:10.1016/j.molmet.2019.07.008
    1. Liu J, Conde K, Zhang P, et al. Enhanced AMPA receptor trafficking mediates the anorexigenic effect of endogenous glucagon-like peptide-1 in the paraventricular hypothalamus. Neuron. 2017;96(4):897–909.e895. doi:10.1016/j.neuron.2017.09.042
    1. Abtahi S, Howell E, Salvucci JT, Bastacky JMR, Dunn DP, Currie PJ. Exendin-4 antagonizes the metabolic action of acylated ghrelinergic signaling in the hypothalamic paraventricular nucleus. Gen Comp Endocrinol. 2019;270:75–81. doi:10.1016/j.ygcen.2018.10.008
    1. Williams DL, Lilly NA, Edwards IJ, Yao P, Richards JE, Trapp S. GLP-1 action in the mouse bed nucleus of the stria terminalis. Neuropharmacology. 2018;131:83–95. doi:10.1016/j.neuropharm.2017.12.007
    1. Zheng H, Reiner DJ, Hayes MR, Rinaman L. Chronic suppression of glucagon-like peptide-1 receptor (GLP1R) mRNA translation in the rat bed nucleus of the stria terminalis reduces anxiety-like behavior and stress-induced hypophagia, but prolongs stress-induced elevation of plasma corticosterone. J Neurosci. 2019;39(14):2649–2663. doi:10.1523/JNEUROSCI.2180-18.2019
    1. Alhadeff AL, Baird JP, Swick JC, Hayes MR, Grill HJ. Glucagon-like peptide-1 receptor signaling in the lateral parabrachial nucleus contributes to the control of food intake and motivation to feed. Neuropsychopharmacology. 2014;39(9):2233–2243. doi:10.1038/npp.2014.74
    1. Hsu TM, Hahn JD, Konanur VR, Lam A, Kanoski SE. Hippocampal GLP-1 receptors influence food intake, meal size, and effort-based responding for food through volume transmission. Neuropsychopharmacology. 2015;40(2):327–337. doi:10.1038/npp.2014.175
    1. Alhadeff AL, Grill HJ. Hindbrain nucleus tractus solitarius glucagon-like peptide-1 receptor signaling reduces appetitive and motivational aspects of feeding. Am J Physiol Regul Integr Comp Physiol. 2014;307(4):R465–470. doi:10.1152/ajpregu.00179.2014
    1. Wang XF, Liu JJ, Xia J, Liu J, Mirabella V, Pang ZP. Endogenous glucagon-like peptide-1 suppresses high-fat food intake by reducing synaptic drive onto mesolimbic dopamine neurons. Cell Rep. 2015;12(5):726–733. doi:10.1016/j.celrep.2015.06.062
    1. Howell E, Baumgartner HM, Zallar LJ, Selva JA, Engel L, Currie PJ. Glucagon-like peptide-1 (GLP-1) and 5-hydroxytryptamine 2c (5-HT(2c)) receptor agonists in the ventral tegmental area (VTA) inhibit ghrelin-stimulated appetitive reward. Int J Mol Sci. 2019;20(4):889. doi:10.3390/ijms20040889
    1. Sørensen G, Reddy IA, Weikop P, et al. The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice. Physiol Behav. 2015;149:262–268. doi:10.1016/j.physbeh.2015.06.013
    1. Hernandez NS, O’Donovan B, Ortinski PI, Schmidt HD. Activation of glucagon-like peptide-1 receptors in the nucleus accumbens attenuates cocaine seeking in rats. Addict Biol. 2019;24(2):170–181. doi:10.1111/adb.12583
    1. Pierce-Messick Z, Pratt WE. Glucagon-like peptide-1 receptors modulate the binge-like feeding induced by µ-opioid receptor stimulation of the nucleus accumbens in the rat. Neuroreport. 2020;31(18):1283–1288. doi:10.1097/WNR.0000000000001545
    1. Parker JA, McCullough KA, Field BC, et al. Glucagon and GLP-1 inhibit food intake and increase c-fos expression in similar appetite regulating centres in the brainstem and amygdala. Int J Obes (Lond). 2013;37(10):1391–1398. doi:10.1038/ijo.2012.227
    1. Anderberg RH, Anefors C, Bergquist F, Nissbrandt H, Skibicka KP. Dopamine signaling in the amygdala, increased by food ingestion and GLP-1, regulates feeding behavior. Physiol Behav. 2014;136:135–144. doi:10.1016/j.physbeh.2014.02.026
    1. Gil-Lozano M, Romaní-Pérez M, Outeiriño-Iglesias V, et al. Corticotropin-releasing hormone and the sympathoadrenal system are major mediators in the effects of peripherally administered exendin-4 on the hypothalamic-pituitary-adrenal axis of male rats. Endocrinology. 2014;155(7):2511–2523. doi:10.1210/en.2013-1718
    1. Gil-Lozano M, Romaní-Pérez M, Outeiriño-Iglesias V, et al. Effects of prolonged exendin-4 administration on hypothalamic-pituitary-adrenal axis activity and water balance. Am J Physiol Endocrinol Metab. 2013;304(10):E1105–1117. doi:10.1152/ajpendo.00529.2012
    1. Farr OM, Upadhyay J, Rutagengwa C, et al. Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: implications for plateauing weight loss in response to anti-obesity therapies. Diabetes Obes Metab. 2019;21(11):2459–2464. doi:10.1111/dom.13827
    1. Zanchi D, Depoorter A, Egloff L, et al. The impact of gut hormones on the neural circuit of appetite and satiety: a systematic review. Neurosci Biobehav Rev. 2017;80:457–475. doi:10.1016/j.neubiorev.2017.06.013
    1. Winzeler B, da Conceição I, Refardt J, Sailer CO, Dutilh G, Christ-Crain M. Effects of glucagon-like peptide-1 receptor agonists on fluid intake in healthy volunteers. Endocrine. 2020;70(2):292–298. doi:10.1007/s12020-020-02394-2
    1. Beiroa D, Imbernon M, Gallego R, et al. GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. Diabetes. 2014;63(10):3346–3358. doi:10.2337/db14-0302
    1. Liao T, Zhang SL, Yuan X, et al. Liraglutide lowers body weight set point in DIO rats and its relationship with hypothalamic microglia activation. Obesity (Silver Spring). 2020;28(1):122–131. doi:10.1002/oby.22666
    1. Davis EM, Sandoval DA. Glucagon-like peptide-1: actions and influence on pancreatic hormone function. Compr Physiol. 2020;10(2):577–595.
    1. Kumari P, Nakata M, Zhang BY, Otgon-Uul Z, Yada T. GLP-1 receptor agonist liraglutide exerts central action to induce β-cell proliferation through medulla to vagal pathway in mice. Biochem Biophys Res Commun. 2018;499(3):618–625. doi:10.1016/j.bbrc.2018.03.199
    1. Katsurada K, Nakata M, Saito T, et al. Central glucagon-like peptide-1 receptor signaling via brainstem catecholamine neurons counteracts hypertension in spontaneously hypertensive rats. Sci Rep. 2019;9(1):12986. doi:10.1038/s41598-019-49364-x
    1. Terrill SJ, Maske CB, Williams DL. Endogenous GLP-1 in lateral septum contributes to stress-induced hypophagia. Physiol Behav. 2018;192:17–22. doi:10.1016/j.physbeh.2018.03.001
    1. Jerlhag E. GLP-1 signaling and alcohol-mediated behaviors; preclinical and clinical evidence. Neuropharmacology. 2018;136(Pt B):343–349. doi:10.1016/j.neuropharm.2018.01.013
    1. Hayes MR, Schmidt HD. GLP-1 influences food and drug reward. Curr Opin Behav Sci. 2016;9:66–70. doi:10.1016/j.cobeha.2016.02.005
    1. Kellar D, Craft S. Brain insulin resistance in Alzheimer’s disease and related disorders: mechanisms and therapeutic approaches. Lancet Neurol. 2020;19(9):758–766. doi:10.1016/S1474-4422(20)30231-3
    1. Jurczak MJ, Lee HY, Birkenfeld AL, et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes. 2011;60(3):890–898. doi:10.2337/db10-1328
    1. Jurczak MJ, Saini S, Ioja S, et al. SGLT2 knockout prevents hyperglycemia and is associated with reduced pancreatic β-cell death in genetically obese mice. Islets. 2018;10(5):181–189. doi:10.1080/19382014.2018.1503027
    1. Asferg CL, Nielsen SJ, Andersen UB, et al. Relative atrial natriuretic peptide deficiency and inadequate renin and angiotensin II suppression in obese hypertensive men. Hypertension. 2013;62(1):147–153. doi:10.1161/HYPERTENSIONAHA.111.00791
    1. Grassi G, Seravalle G, Cattaneo BM, et al. Sympathetic activation in obese normotensive subjects. Hypertension. 1995;25(4 Pt 1):560–563.
    1. Tanaka M, Itoh H. Hypertension as a metabolic disorder and the novel role of the gut. Curr Hypertens Rep. 2019;21(8):63. doi:10.1007/s11906-019-0964-5
    1. Umino H, Hasegawa K, Minakuchi H, et al. High basolateral glucose increases sodium-glucose cotransporter 2 and reduces sirtuin-1 in renal tubules through glucose transporter-2 detection. Sci Rep. 2018;8(1):6791. doi:10.1038/s41598-018-25054-y
    1. Erdogan MA, Yusuf D, Christy J, et al. Highly selective SGLT2 inhibitor dapagliflozin reduces seizure activity in pentylenetetrazol-induced murine model of epilepsy. BMC Neurol. 2018;18(1):81. doi:10.1186/s12883-018-1086-4
    1. Chiba Y, Yamada T, Tsukita S, et al. Dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, acutely reduces energy expenditure in BAT via neural signals in mice. PLoS One. 2016;11(3):e0150756.
    1. Tahara A, Kondo Y, Takasu T, Tomiyama H. Effects of the SGLT2 inhibitor ipragliflozin on food intake, appetite-regulating hormones, and arteriovenous differences in postprandial glucose levels in type 2 diabetic rats. Biomed Pharmacother. 2018;105:1033–1041. doi:10.1016/j.biopha.2018.06.062
    1. Matthews JR, Herat LY, Magno AL, Gorman S, Schlaich MP, Matthews VB. SGLT2 inhibitor-induced sympathoexcitation in white adipose tissue: a novel mechanism for beiging. Biomedicines. 2020;8(11):514. doi:10.3390/biomedicines8110514
    1. Rahman A, Fujisawa Y, Nakano D, Hitomi H, Nishiyama A. Effect of a selective SGLT2 inhibitor, luseogliflozin, on circadian rhythm of sympathetic nervous function and locomotor activities in metabolic syndrome rats. Clin Exp Pharmacol Physiol. 2017;44(4):522–525. doi:10.1111/1440-1681.12725
    1. Nguyen T, Wen S, Gong M, et al. Dapagliflozin activates neurons in the central nervous system and regulates cardiovascular activity by inhibiting SGLT-2 in mice. Diabetes Metab Syndr Obes. 2020;13:2781–2799. doi:10.2147/DMSO.S258593

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi